News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,736 Results
Type
Article (43683)
Company Profile (473)
Press Release (693568)
Multimedia
Podcasts (122)
Webinars (20)
Section
Business (209307)
Career Advice (2047)
Deals (36152)
Drug Delivery (119)
Drug Development (83958)
Employer Resources (174)
FDA (16684)
Job Trends (15185)
News (354137)
Policy (33278)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2655)
Accelerated approval (34)
Adcomms (28)
Allergies (141)
Alliances (51112)
ALS (176)
Alzheimer's disease (1718)
Antibody-drug conjugate (ADC) (325)
Approvals (16920)
Artificial intelligence (533)
Autoimmune disease (149)
Automation (37)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (59)
Breast cancer (645)
Cancer (4891)
Cardiovascular disease (414)
Career advice (1731)
Career pathing (37)
CAR-T (287)
CDC (46)
Celiac Disease (2)
Cell therapy (767)
Cervical cancer (36)
Clinical research (71376)
Collaboration (1768)
Company closure (4)
Compensation (1160)
Complete response letters (62)
COVID-19 (2769)
CRISPR (96)
C-suite (854)
Cystic fibrosis (152)
Data (6251)
Decentralized trials (2)
Denatured (39)
Depression (141)
Diabetes (500)
Diagnostics (6733)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (258)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (239)
Earnings (91321)
Editorial (59)
Employer branding (21)
Employer resources (152)
Events (120921)
Executive appointments (993)
FDA (19804)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1514)
Gene editing (211)
Generative AI (44)
Gene therapy (635)
GLP-1 (1006)
Government (4752)
Grass and pollen (6)
Guidances (384)
Healthcare (19202)
HIV (57)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (270)
Immuno-oncology (58)
Indications (104)
Infectious disease (3033)
Inflammatory bowel disease (196)
Inflation Reduction Act (17)
Influenza (113)
Intellectual property (247)
Interviews (316)
IPO (16929)
IRA (52)
Job creations (3712)
Job search strategy (1447)
JPM (65)
Kidney cancer (15)
Labor market (83)
Layoffs (580)
Leadership (32)
Legal (8027)
Liver cancer (93)
Longevity (14)
Lung cancer (658)
Lymphoma (377)
Machine learning (43)
Management (59)
Manufacturing (797)
MASH (169)
Medical device (13909)
Medtech (13961)
Mergers & acquisitions (20290)
Metabolic disorders (1305)
Multiple sclerosis (160)
NASH (19)
Neurodegenerative disease (332)
Neuropsychiatric disorders (95)
Neuroscience (2991)
Neurotech (1)
NextGen: Class of 2026 (6771)
Non-profit (4581)
Now hiring (65)
Obesity (624)
Opinion (280)
Ovarian cancer (166)
Pain (202)
Pancreatic cancer (229)
Parkinson's disease (294)
Partnered (34)
Patents (491)
Patient recruitment (484)
Peanut (56)
People (60258)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22452)
Phase 2 (31468)
Phase 3 (23269)
Pipeline (5146)
Policy (294)
Postmarket research (2602)
Preclinical (9600)
Press Release (67)
Prostate cancer (243)
Psychedelics (55)
Radiopharmaceuticals (296)
Rare diseases (875)
Real estate (6063)
Recruiting (70)
Regulatory (24943)
Reports (51)
Research institute (2482)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (253)
Series B (196)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3803)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (81)
Vaccines (1014)
Venture capital (93)
Weight loss (405)
Women's health (89)
Worklife (19)
Date
Today (33)
Last 7 days (610)
Last 30 days (2398)
Last 365 days (30687)
2026 (2907)
2025 (31063)
2024 (36297)
2023 (41015)
2022 (52279)
2021 (56765)
2020 (54922)
2019 (47418)
2018 (35700)
2017 (33024)
2016 (32351)
2015 (38400)
2014 (32186)
2013 (27114)
2012 (29222)
2011 (29865)
2010 (27994)
Location
Africa (755)
Alabama (89)
Alaska (7)
Arizona (314)
Arkansas (14)
Asia (40674)
Australia (6759)
California (11380)
Canada (3274)
China (1125)
Colorado (481)
Connecticut (489)
Delaware (335)
Europe (89133)
Florida (1671)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (876)
India (63)
Indiana (519)
Iowa (24)
Japan (425)
Kansas (129)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1395)
Massachusetts (8273)
Michigan (322)
Minnesota (634)
Mississippi (5)
Missouri (127)
Montana (33)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3029)
New Mexico (31)
New York (2980)
North Carolina (1517)
North Dakota (9)
Northern California (5522)
Ohio (334)
Oklahoma (21)
Oregon (45)
Pennsylvania (2281)
Puerto Rico (22)
Rhode Island (48)
South America (1122)
South Carolina (65)
South Dakota (1)
Southern California (4412)
Tennessee (173)
Texas (1748)
United States (40482)
Utah (339)
Vermont (1)
Virginia (264)
Washington D.C. (82)
Washington State (951)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
737,736 Results for "spiral therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space
Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief Clinical Officer Lynn Kramer expressed unwavering conviction in his company’s own anti-tau asset, while others suggest the Alzheimer’s field is heading in a completely different direction.
December 5, 2025
·
4 min read
·
Heather McKenzie
Biotech Bay
Spiral Therapeutics Announces Collaboration with the Vestibular Disorders Association (VeDA), Advancing Patient-Centric Care in Neurotology
Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage pharmaceutical company leading the way in therapies for inner ear disorders, today announced a strategic partnership with the Vestibular Disorders Association (VeDA).
October 31, 2023
·
2 min read
Biotech Bay
Spiral Therapeutics Welcomes New Investment, Cementing Its Leadership in Neurotology
Spiral Therapeutics, Inc., a clinical-stage company focused on delivering therapies for inner ear disorders, announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.
August 30, 2023
·
2 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Deals
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.
March 29, 2023
·
4 min read
Press Releases
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
January 16, 2026
·
8 min read
Press Releases
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
February 3, 2026
·
2 min read
Press Releases
Zevra Therapeutics, Inc. Announces CFO Transition
November 21, 2025
·
3 min read
Press Releases
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 13, 2026
·
7 min read
1 of 73,774
Next
